In this issue:
CAR-NK cells in CD19-positive lymphoid tumours
Influence of age on ICI efficacy in advanced cancers
Adverse events with immunotherapeutics vs. chemotherapy in solid organ tumours
CD19/22 CAR T-cell therapy in refractory/relapsed B-cell malignancies
Response patterns in melanoma treated with ipilimumab + anti-PD-1
ICIs + chemotherapy for advanced pancreatic cancer
Pembrolizumab in non-colorectal high-MSI/mismatch repairdeficient cancers
Pembrolizumab as second-line for advanced HCC
CD22 CAR T-cells in refractory/relapsed B-ALL
CAR T-cell therapies for B-cell lymphomas
Please login below to download this issue (PDF)